Educational overview · Approx. 4 min read · illustrative, not advice
The case for a cash-pay model rests on two coverage mechanisms that are structural rather than temporary. Both are dated, both are sourced, and both can change.
Mechanism one: the Medicare exclusion is statutory
Medicare Part D has been prohibited by statute from covering drugs used for weight loss since the program was created under the 2003 Medicare Modernization Act. Access under an obesity indication exists only where another medically accepted indication applies. This is not a coverage policy that a plan can revise; it is legislation.
Two temporary programs sit on top of that exclusion. The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027 at a $50 monthly copay, and those copays do not count toward Part D deductibles or out-of-pocket maximums. The BALANCE model began for Medicaid in May 2026 and was delayed indefinitely for Medicare Part D after plan participation fell short of an 80% enrollment threshold. State and plan participation in both is voluntary.
Read those two paragraphs together. The permanent structure is exclusion. The relief is temporary, partial, voluntary, and in one case already stalled.
Mechanism two: employer coverage is a minority position below the largest firms
KFF's 2025 Employer Health Benefits Survey, fielded January through July 2025 across 1,862 firms, found that among firms offering health benefits, 16% of firms with 200 to 999 workers cover GLP-1 agonists used primarily for weight loss, rising to 30% at 1,000 to 4,999 workers and 43% at 5,000 or more.
Coverage at the largest firms is growing fast, from 28% in 2024 to 43% in 2025. But the same survey shows why that growth is not safely extrapolated: 59% of the largest covering firms reported utilisation above projections and 66% reported significant impact on prescription drug spending. Thirty-four percent of covering firms required a provider visit or lifestyle program participation as a condition.
That last requirement is worth pausing on. Employers who do cover are increasingly attaching a clinical-touch or program condition, which is a demand signal for structured programs rather than for drugs alone.
What the two mechanisms produce
Cash-pay demand in this category is produced by a statutory Medicare exclusion addressed only through temporary voluntary programs, plus majority non-coverage of the weight-loss indication among mid-sized employers. We label this INFERENCE: no single publisher states it as a conclusion, and it is a characterisation of the coverage landscape, not a demand forecast and not a statement about any operator's results.
The distinction matters because a demand argument built on a temporary supply shortage expires when the shortage does. That is precisely what happened to a large part of this category in 2025, and page nine covers it. A demand argument built on statute and benefit design has a different half-life.
The counterweight: direct-to-consumer pricing is falling
Manufacturers now sell directly. Wegovy self-pay pricing through NovoCare Pharmacy starts at $149 per month for the 1.5 mg or 4 mg oral doses for new patients, with the standard pen starting at $199 per month for the first two months as a limited-time offer and the HD 7.2 mg pen from $399 per month after the introductory period, all stated as subject to change and checked August 2026.
On November 6, 2025 the White House announced agreements with Eli Lilly and Novo Nordisk placing starting doses at $350 per month via the TrumpRx direct-to-consumer site that launched in January 2026, trending toward $245 over two years, with Medicare prices set at $245 and a $50 beneficiary copay, and approximately $150 per month for oral GLP-1s if approved.
If your model's value proposition is access to a molecule at a price, that proposition is being competed away by the manufacturers themselves. This is the single most important strategic fact on this page and it argues for building a program, not a pharmacy counter.
What survives the pricing pressure
What manufacturers are not selling direct is the wrapper: clinical oversight through a separately licensed medical entity, structured nutrition and behaviour support, lab work and monitoring, adherence coaching, and a member experience someone stays inside for a year rather than a quarter. The affordability data on page three is a strong hint that people leave for cost reasons long before they leave for clinical ones.
A cash-pay metabolic business in 2026 is a program business with a medication component, not a medication business with a program veneer. Page eleven argues that retention is where that distinction gets paid for.
- KFF (Medicare policy analysis) — Medicare Part D has been prohibited by statute from covering drugs used for weight loss since the 2003 Medicare Modernization Act; the Medicare GLP-1 Bridge runs July 1, 2026-December 31, 2027 at a $50 monthly copay that does not count toward Part D deductibles or out-of-pocket maximums; the BALANCE model began for Medicaid in May 2026 and was delayed indefinitely for Medicare Part D after plan participation fell short of an 80% enrollment threshold; state and plan participation are voluntary. (source) [VERIFIED]
- KFF 2025 Employer Health Benefits Survey (fielded January-July 2025; 1,862 firms) — 16% of firms with 200-999 workers, 30% with 1,000-4,999 and 43% with 5,000+ cover GLP-1 agonists used primarily for weight loss; largest-firm coverage rose from 28% in 2024 to 43% in 2025; 59% of the largest covering firms reported utilisation above projections; 66% reported significant prescription drug spending impact; 34% of covering firms required a provider visit or lifestyle program. (source) [VERIFIED]
- Novo Nordisk / NovoCare Pharmacy (manufacturer page, checked August 2026) — Wegovy self-pay from $149/month for 1.5 mg or 4 mg oral doses for new patients; standard pen from $199/month for the first two months as a limited-time offer; HD 7.2 mg pen from $399/month after the introductory period. Subject to change. (source) [VERIFIED]
- CNBC — November 6, 2025 White House agreements with Eli Lilly and Novo Nordisk: starting doses at $350/month via TrumpRx launching January 2026, trending to $245 over two years; Medicare price $245 with $50 beneficiary copay; approximately $150/month for oral GLP-1s if approved. (source) [VERIFIED]
- Reasoned from KFF coverage data, CDC prevalence data and FDA compounding actions — Cash-pay demand in this category is produced by durable structural mechanisms rather than a temporary supply or pricing condition. A characterisation of the coverage landscape, not a demand forecast and not a statement about any operator's results. [INFERENCE]